19 related articles for article (PubMed ID: 38474205)
1. Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.
Lin Y; Li D; Hui H; Miao H; Luo M; Roy B; Chen B; Zhang W; Shao D; Ma D; Jie Y; Qiu F; Li H; Jiang B
Front Oncol; 2024; 14():1389618. PubMed ID: 38803537
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies.
Nakamura H; Koizumi H; Kimura H; Marushima H; Saji H; Takagi M
Lung Cancer; 2016 Sep; 99():143-7. PubMed ID: 27565930
[TBL] [Abstract][Full Text] [Related]
3. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
4. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
5. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
6. Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
Ishida H; Shimizu Y; Sakaguchi H; Nitanda H; Kaneko K; Yamazaki N; Yanagihara A; Taguchi R; Sakai F; Yasuda M; Kobayashi K
Lung Cancer; 2019 Mar; 129():16-21. PubMed ID: 30797486
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Petterson J; Mustafa D; Bandaru S; Eklund EÄ; Hallqvist A; Sayin VI; Gagné A; Fagman H; Akyürek LM
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474205
[TBL] [Abstract][Full Text] [Related]
8. Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.
Behera M; Owonikoko TK; Gal AA; Steuer CE; Kim S; Pillai RN; Khuri FR; Ramalingam SS; Sica GL
Clin Lung Cancer; 2016 Sep; 17(5):e57-e64. PubMed ID: 27137345
[TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Chalela R; Curull V; Enríquez C; Pijuan L; Bellosillo B; Gea J
J Thorac Dis; 2017 Jul; 9(7):2142-2158. PubMed ID: 28840016
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]